We are proud to have successfully treated the first SLE patient in Australia with YTB323 (Novartis), a cutting-edge CAR-T cell therapy. Although this study is now closed to recruitment, it represents a major advancement in the treatment of autoimmune conditions.
Monash Nephrology are currently recruiting Lupus Nephritis patients for the Phase II YTB study.
We are currently recruiting for a new allogeneic CAR-T cell therapy study targeting:
This study uses a novel CAR-T product developed by Sana Biotechnology Inc., aiming to deliver transformative outcomes for patients with severe, treatment-resistant autoimmune diseases.
Only a few spots left globally so please get in touch.
We are also recruiting for a Phase III clinical trial investigating the efficacy and safety of Efgartigimod, a therapy designed to reduce disease-causing IgG antibodies.
Patients diagnosed with Sjögren’s Disease who meet eligibility criteria are encouraged to participate.
For referrals or more information, contact:
Professor Alberta Hoi – RheumatologyClinicalTrials@monashhealth.org
Launching in 2026, a second allogeneic CAR-T study will focus on:
These studies are conducted in close partnership with Monash Haematology, reinforcing our commitment to collaborative, multidisciplinary care and research excellence.
For referrals or more information, contact:
Professor Eric Morand – RheumatologyClinicalTrials@monashhealth.org
Please click the link below to view all current clinical trials – updated quarterly with new trials.
PDF document